Abstract
The present invention relates to peptides comprising analogues of VDAC1- derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto
| Original language | English |
|---|---|
| Patent number | AU2016314372 |
| IPC | C07K 14/ 08 A I |
| Priority date | 1/09/16 |
| State | Published - 26 Apr 2018 |